Effect of Moisturising Creams on Skin Moisture in Atopic Dermatitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is evaluate the effect of three moisturising creams on Stratum corneum (SC) hydratation and barrier function.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Moisturizing Creams on Skin Barrier Function

NCT00771121

Atopic Eczema

UNKNOWN PHASE4

Clinical-Instrumental Study To Evaluate And Compare The Efficacy And Tolerability Of Two Emollients Products In Atopic Dermatitis

NCT06930365

Atopic Dermatitis Eczema

RECRUITING NA

Impact of the Daily Use of Emollient on Corticosteroids Consumption in Patients With Atopic Dermatitis

NCT05644691

Atopic Dermatitis

COMPLETED

Assessment of Skin Tolerance and Efficacy of a Cosmetic Product After 5 Days of Use on Subjects With Atopic Dermatitis

NCT05807113

Atopic Diathesis Eczema-prone Skin

COMPLETED NA

Efficacy Evaluation and Cutaneous Acceptibility of a Dermocosmetic Product on Subjects Suffering of Atopic Dermatisis.

NCT06756438

Atopic Dermatitis Eczema

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In the present study, 24 subjects with AD will be treated for 3 weeks twice daily by using 3 different moisturising creams. Duration of the study is based on literature. Various moisturising creams containing glycerol have been reported to be beneficial for AD lesions. The optimal glycerol content in moisturising creams is not known. The secondary objective is the comparison of change in the SC water content and in the TEWL from the skin surface from the baseline to the end of study between different moisturizing creams containing different amount of glycerol.

Change in the SC water content and in the TEWL can be demonstrated with noninvasive instrumental measurement. The treated skin will be followed up instrumentally, and one measurement area will serve as an untreated control. The primary evaluation is the comparison of change in the SC water content and in the TEWL on the skin surface from the baseline to the end of study between the 4 treatments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dermatitis, Atopic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Moisturising cream

Group Type EXPERIMENTAL

Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%

Intervention Type OTHER

moisturising cream twice daily three weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%

moisturising cream twice daily three weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent (IC) obtained.
2. 18-55 years of age, Caucasian, Finnish speaking, male or female subjects.
3. Weight at least 50 kg.
4. Body mass index (BMI) 18-30 kg/m2.
5. Clinical assessment for the diagnosis of mild or moderate atopic dermatitis

Exclusion Criteria

1. Any clinically relevant medical condition judged by the investigator.
2. Any known allergy to ingredients of the test treatments.
3. Any systemic immunosuppressive or cortisone medication.
4. UV-Light therapy and sunlight exposure within 30 days prior to the start of the study and during study.
5. Any abnormal physical finding which may interfere with the interpretation of test results or cause a health risk for the subject if he/she participates in the study.
6. Anticipated difficulty related to stopping of caffeine intake during study centre visits.
7. Current use of nicotine containing products more than 5 cigarettes (or equivalent)/day and inability to refrain from the use of nicotine containing products during the study.
8. Recent or current drug abuse or suspected abuse or positive result in screening of drug abuse.
9. Recent or current alcohol abuse (more than 16 units/week for women and more than 21 units/week for men) or suspected abuse.
10. Participation in another clinical study within 30 days prior to the start of the present study.
11. Predictable poor compliance or inability to communicate well with the investigator.
12. Inability to participate in all treatment periods.
13. Pregnant or lactating females.
14. Females of childbearing potential if they are not using proper contraception (hormonal contraception, intrauterine device (IUD) or surgical sterilization, spermicidal foam in conjunction with condom on male partner) (Note: women of childbearing potential with no current sexual relationship can be included without contraception according to the judgement of the investigator).

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No